Future of Missouri's low-income utility assistance program uncertain after federal cuts
Included in the massive federal workforce cuts at the Department of Health and Human Services this week was the elimination of an office that runs a program over 100,000 Missouri families rely on to help pay their heating and cooling bills.
The layoffs within the Low Income Home Energy Assistance Program, which provides Congressionally-approved funds that are administered by Missouri's social services department, leaves the program's future in limbo.
LIHEAP is designed to help those with few resources cover their home energy bills in the summer and winter. Since October, the program has helped offset utility costs for 100,839 households, according to a spokesperson for the Department of Social Services.
The state received over $136.4 million for the program in fiscal year 2023, and the average benefit for the heating and cooling program was around $675 per household.
The Department of Social Services has 'not received any official updates regarding potential program reductions,' said spokesperson Baylee Watts, and the federal government hasn't announced program cuts. But advocates fear that without the federal staff, the future allocation of funding is uncertain.
'Any cuts to LIHEAP will be detrimental to Missourians who are already struggling to keep up with increasing electric and gas bills,' said Sandra Padgett, executive director of Consumers Council of Missouri, in a press release.
States are still waiting for around 10% of their annual funding allocation for the federal fiscal year that began in October. That amount usually arrives in June. Watts said Missouri hasn't been notified yet of what that amount is, but it was $8.1 million last year.
Those funds aren't expected to be needed until the fiscal year that starts in October, though, Watts said, based on the way Missouri has allocated funding.
'At this moment, DSS does not anticipate any impact on services,' Watts said.
At the same time, a bill adding a charge onto utility bills passed the state legislature and is awaiting the governor's signature.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Tonix announces FDA approval of Tonmya for treatment of fibromyalgia
Tonix Pharmaceuticals (TNXP) Holding Corp. announced that the FDA approved Tonmya for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (greater than or equal to30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. Elevate Your Investing Strategy:
Indianapolis Star
2 days ago
- Indianapolis Star
Parachute expands New Baby Collection: Shop crib sheets, hooded towels
Everything leading up to a new baby is one big, beautiful countdown. First, you create the registry, then you celebrate with a baby shower (or a gender reveal, if you're into that sort of thing) and soon you'll find yourself happily nesting as you get the nursery just right. Once your little one arrives, you'll be focused on keeping them cozy and comfortable—and that's where Parachute's new Baby Collection comes in. They've created a line of beautiful essentials designed with both baby and parent in mind. Parachute Home's New Baby Collection has everything covered from nap time to bath time. You can find light, breathable sheets to provide comfort in their crib, to adorable and organic hooded towels for bath time. Here's a sneak peek at some of the newly added items to the New Baby Collection that caught our eye, so be sure to grab them now to help ease your mind. Money-saving tip: New shoppers can get a 15% welcome discount on their first order just by signing up for Parachute's emails. To get your unique promo code, just go to Parachute's website and a pop-up should appear where you can enter your email address. If you don't see it, simply scroll to the bottom of the page and enter your email in the box that says "Cozy updates + a discount on your first order!" Your welcome offer will be sent to your inbox within seconds! Shop Parachute's New Baby Collection More: Save up to 40% on Brooklinen sheet sets, bath essentials and viral waffle robes More: Exclusive: Save 35% on Cozy Earth's Oprah-approved sheets, PJs with our promo code Parachute Home stands out for its premium, breathable materials with a softness that lasts for years. You're investing in bedding that feels like you're getting into a resort bed every time you lie down. Many products at Parachute are made without harmful chemicals and with a dedication to environmental responsibility, so you can feel good about your investment even when you aren't lying in bed.
Yahoo
2 days ago
- Yahoo
Trump targets bolstering of US emergency drug reserve
US President Donald Trump has ordered the bolstering of the country's Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with important drugs, aligning with his wider ambition to reduce reliance on imported pharmaceutical products. The executive order, signed on 13 August, will see the active pharmaceutical ingredients (API) of around 26 'critical drugs' added to the SAPIR. Trump has directed the Office of the Assistant Secretary for Preparedness and Response (ASPR) to curate the list of drugs whose APIs will be stored. The office of the ASPR is within the US Department of Health and Human Services (HHS) and is responsible for safeguarding drugs involved in the country's public health strategies. The SAPIR was established in 2020 by the Trump administration in response to the Covid-19 pandemic. The reserve is supposed to have nearly two years' worth of medicine supply for the most important treatments approved by the US Food and Drug Administration (FDA), but a lack of investment means it has been near-empty for the past few years. The White House blames the Biden administration for failing to advance domestic production or fill the SAPIR, 'despite spending billions on supply chain initiatives'. Trump has requested a shorter timeframe for how long the repository should be able to provide the 26 drugs in the event of an emergency. The ASPR is tasked with obtaining a six-month supply of the critical APIs. It also instructed to update the 2022 list of 86 essential medicines, with a six-month supply planned too. The executive order has asked the ASPR to preferentially source the API via 'domestically manufactured' means. However, the office might have its work cut out to find these providers, given how reliant the US is on importing APIs. Of the manufacturers that produce APIs used in FDA-approved products, only 11% are based in the US. Around 43% of branded pharmaceutical API come from the EU. In a statement, the White House said the move to fill the SAPIR with more drugs 'addresses supply chain vulnerabilities'. A spokesperson added: 'Restoring capacity for domestic production of essential pharmaceutical products is essential to safeguarding national health and security against global supply chain disruptions.' The SAPIR executive order is part of Trump's strategy to bolster domestic pharma manufacturing. This has mainly been mediated via tariffs and economic policies. Last week, the FDA introduced a new scheme that will streamline the introduction of new pharmaceutical manufacturing facilities in the US. The PreCheck programme, unveiled by the agency on 7 August, comprises a two-phase approach to facilitate new US drug manufacturing facilities. Big pharma has been responding to Trump's pressurised calls by outlaying significant funds to boost US manufacturing sites. Johnson & Johnson is set to invest $55bn over the next four years, including a $2bn biologics production site in North Carolina that promises to create 500 jobs. Roche outlaid a similar amount, planning $50bn worth of investment in the US, which will generate more than 1,000 jobs in new and expanded facilities. "Trump targets bolstering of US emergency drug reserve" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
